Following a request from the European Commission, EFSA was asked to review the scientific comments received on the Scientific Opinion of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi07 contributes to increasing lactose digestion pursuant to Article 13.5 of Regulation (EC) No 1924/2006. Comments originating from the applicant (DuPont) were submitted to EFSA via the European Commission Services. EFSA has reviewed the comments with the contribution of the chair of the NDA Working Group on Claims, the chair of the NDA Panel and the Working Group on Claims of the NDA Panel. In its opinion adopted on 1July 2020 the EFSA Panel on Nutrition, Novel Foods andFood Allergens (NDA) concluded that a cause and effect relationship has not been established between the consumption ofBifidobacterium animalis subsp. lactis Bi07 and a beneficial physiological effect (i.e. the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion. The comments received do not require any change in the conclusions of the NDA Panel.